High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature

Zhang

Bai

et al. 2021

Sci Rep

Cerebral venous sinus thrombosis (CVST) is a rare and devastating complication of inflammatory bowel disease (IBD). Early diagnosis and prompt treatment could improve prognosis. The aim of our study was to investigate the clinical data and predictive factors of inflammatory bowel disease in patients with a diagnosis of CVST. All IBD patient data were collected from July 2013 and September 2020. Clinical data, predictive factors and prognosis were compared between IBD patients with CVST and the IBD control group. The incidence of CVST in our study was 0.48%. The mean age of IBD patients with CVST was 34.9 years. The average duration of IBD was 4 years when cerebrovascular events occurred. The clinical presentation of CVST included headache (73.1%), vomiting (30.8%), limb dysmetria (26.9%), speech impairment (11.5%), blurred vision (7.7%), epileptic seizures (7.7%) and drowsiness (3.8%). The most common location for CVST was the transverse sinus (61.5%) followed by the superior sagittal sinus (30.8%). Anaemia, low albumin and elevated d-dimer were independent predictors of CVST in patients with IBD. Anticoagulation therapy was effective. The prognosis of IBD patients with CVST was worse than that of IBD patients without CVST. Early identification of the risk and clinical features of CVST in IBD patients is important. Prompt antithrombotic therapy is a safe and effective treatment.

Section: Discussionmentioning

confidence: 99%

Cerebral venous sinus thrombosis in patients with inflammatory bowel disease: a retrospective study

Zhang

Bai

et al. 2021

Sci Rep

“…Further studies are needed to evaluate its role in CVST. Thiopurines and antitumor necrosis factor (TNF), due to their anti-in ammatory properties, might lowered the risk of thrombosis events [14] , while some documented high dose of IFX might contribute to CVST [15] . In our study, treatment of IBD did not increase the risk of CVST.…”

Section: Discussionmentioning

confidence: 99%

Cerebral Venous Sinus Thrombosis in Patients With Inflammatory Bowel Disease: A Retrospective Study

Zhang

Bai

et al. 2021

Preprint

BACKGROUND: Cerebral venous sinus thrombosis (CVST) is a rare and devastating complication of inflammatory bowel disease (IBD). Early diagnose and prompt treatment could improve prognosis.AIM: The aim of our study was to investigate the clinical data and risk factors of inflammatory bowel disease with diagnosis of CVST. METHODS: All data of IBD patients were collected from July 2013 and September 2020. Clinical data, risk factors and prognosis were compared between CVST in IBD patients and IBD control group. RESULTS: The incidence of CVST in our study was 0.48%. The mean age of IBD patients with CVST was 34.9 years. Average disease duration of IBD was 4 years when cerebrovascular events occur. Clinical presentation of CVST included headache (73.1%), vomiting (30.8%), limb dysmetria (26.9%), speech impairment (11.5%), blurred vision (7.7%), Epileptic seizures (7.7%) and drowsiness (3.8%). The most common location for CVST was transverse sinus (61.5%), followed by superior sagittal sinus (30.8%). Anemia, low albumin and elevated D-dimer were independent predictors of CVST in IBD patients. Anticoagulation therapy was effective. Prognosis of IBD patients with CVST was worse than those without CVST.CONCLUSION: Early identification the risk of and clinical features of CVST in IBD patients is important. Prompt antithrombotic therapy is safe and effective treatment.

“…This addition of anti-protein components to superhydrophobic materials presents another strategy to enhance blood compatibility. Similarly, a Cu-phenol-amine layer was reported by Tu and others for blood-contacting devices with antibacterial and anticoagulant properties [4]. This was based on the simple ion/molecule co-assembly of Cu(II), herbal polyphenol gallic acid, and cystamine (CySA) to fabricate a copper-phenolic-amine network.…”

Section: Coating and Layered Materialsmentioning

confidence: 93%

“…The presence of clots can result in embolization, device malfunction, hemolysis, or they can become nidi of infection, all with potential life-threatening sequelae. Hence, surface adsorption, adhesion, and activation processes of thrombus formation need to be avoided or minimized [ 1 , 2 , 3 , 4 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…As an alternative approach, synthetic surfaces could be developed to prevent clotting and other unwanted events with blood-contacting devices. For years, researchers have studied the pathophysiology underlying thrombosis induced by blood interaction with synthetic materials and have been developing techniques and rational designs to address these issues and enhance blood compatibility [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ]. Key factors to inhibit unwanted interactions between the blood and surfaces include surface free energy, topography, and wettability [ 1 , 7 , 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recent Developments in Blood-Compatible Superhydrophobic Surfaces

Paul

Stein³

et al. 2022

Polymers

Superhydrophobic surfaces, as indicated in the name, are highly hydrophobic and readily repel water. With contact angles greater than 150° and sliding angles less than 10°, water droplets flow easily and hardly wet these surfaces. Superhydrophobic materials and coatings have been drawing increasing attention in medical fields, especially on account of their promising applications in blood-contacting devices. Superhydrophobicity controls the interactions of cells with the surfaces and facilitates the flowing of blood or plasma without damaging blood cells. The antibiofouling effect of superhydrophobic surfaces resists adhesion of organic substances, including blood components and microorganisms. These attributes are critical to medical applications such as filter membranes, prosthetic heart valves, extracorporeal circuit tubing, and indwelling catheters. Researchers have developed various methods to fabricate blood-compatible or biocompatible superhydrophobic surfaces using different materials. In addition to being hydrophobic, these surfaces can also be antihemolytic, antithrombotic, antibacterial, and antibiofouling, making them ideal for clinical applications. In this review, the authors summarize recent developments of blood-compatible superhydrophobic surfaces, with a focus on methods and materials. The expectation of this review is that it will support the biomedical research field by providing current trends as well as future directions.